Market research
PAA.AU PharmAust Limited
AU AUD Healthcare
Latest close
As of 15 Jan 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 112M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.55
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000PAA1
- Market cap
- 112M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.55
About
About PharmAust Limited
PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.
Research context
PharmAust Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PAA.AU discussion.
5 years, 6 months ago
PharmAust Limited is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 95.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.0.
PharmAust Limited's total revenue sank by 27.2% to $2M since the same quarter in the previous year.
Its net income has dropped by 71.7% to $-832K since the same quarter in the previous year.
Finally, its free cash flow grew by 56.5% to $-314K since the same quarter in the previous year.
Based on the above factors, PharmAust Limited gets an overall score of 2/5.